The GLP-1 Landscape: Semaglutide vs Tirzepatide vs Retatrutide

The GLP-1 agonist category has moved faster than any other peptide class in the last three years. From a single-drug market (semaglutide) to a three-way comparison with genuinely different mechanisms, the landscape in mid-2026 is fundamentally different from what it was in 2024.

Here's how the three leading compounds compare — and why "which GLP-1 should I use?" is a biology question, not a brand question.

Mechanism: Single, Dual, Triple Agonism

Semaglutide (Ozempic/Wegovy) is a pure GLP-1 receptor agonist. It mimics glucagon-like peptide-1, which slows gastric emptying, increases insulin secretion, and reduces appetite through central nervous system signaling. Single-target, well-characterized, extensive trial data.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. It adds glucose-dependent insulinotropic polypeptide (GIP) agonism to GLP-1 activity. The combination produces greater weight loss than GLP-1 agonism alone — SURMOUNT-1 showed 20.9% body-weight reduction over 72 weeks, a significant step above semaglutide's ~15% in STEP trials.

Retatrutide is a triple agonist: GLP-1 + GIP + glucagon receptor. The glucagon component increases energy expenditure — not just appetite suppression, but actual metabolic rate elevation. Phase 2 data published in NEJM (2023) showed ~24% body-weight loss over 48 weeks, the strongest published result of any peptide to date. Phase 3 trials are underway.

Efficacy Comparison (Published Trial Data)

Compound	Trial	Duration	Weight Loss	Mechanism
Semaglutide 2.4mg	STEP 1	68 weeks	~14.9%	GLP-1 only
Tirzepatide 15mg	SURMOUNT-1	72 weeks	~20.9%	GIP + GLP-1
Retatrutide 12mg	Phase 2	48 weeks	~24.2%	GLP-1 + GIP + Glucagon

Important caveat: these are different trials with different populations, not head-to-head comparisons. The dose-escalation schedules, side-effect profiles, and drop-out rates are not directly comparable. But the directional signal is clear — multi-receptor agonism produces greater weight loss than single-receptor agonism.

Side-Effect Profiles

All three share the class-typical GI side effects: nausea, vomiting, diarrhea, constipation. These are dose-dependent and generally diminish over 4–8 weeks of titration.

Semaglutide has the largest safety database (millions of patient-years) and the most characterized long-term profile. Tirzepatide is intermediate. Retatrutide is the newest — the Phase 3 safety data isn't published yet, and the glucagon receptor agonism introduces theoretical cardiac concerns (heart rate elevation) that need longer-term data to resolve.

The trade-off is efficacy versus safety database maturity. Retatrutide produces the strongest results; semaglutide has the longest track record. Tirzepatide sits in the middle on both axes.

Which One Fits Your Biology?

The answer isn't "pick the strongest one." It depends on:

Starting BMI and metabolic profile. Someone with mild overweight and a strong response to GLP-1 agonism may get full results from semaglutide without the side-effect burden of a dual or triple agonist. Someone with class III obesity and metabolic resistance may need the stronger signal of tirzepatide or retatrutide.

Tolerability history. If you've previously responded poorly to GLP-1 agonists (severe nausea, vomiting), a stronger agonist may not be the answer — even if the efficacy data looks better.

Access and cost. Regulatory status varies by region and compound. Compounded versions exist but quality varies dramatically. The same molecule from a 503A compounding pharmacy versus an unregulated vendor are different products in practice.

DNA markers. GLP-1 receptor polymorphisms, CYP metabolism variants, and baseline metabolic markers all influence individual response. A DNA test can surface which compounds your biology favors before you commit to a protocol.

For dosing frameworks, Cycling Peptides: A Protocol Framework. For the full product pages: Semaglutide, Tirzepatide, Retatrutide. The Weight Loss Stack covers how these compounds combine with complementary peptides.